· AIM:Todeterminereallifeclinicaloutcomesinpoorly responsiveandtreatment-na觙veneovascularage-related maculardegeneration(nvAMD)patientsusingbimonthly fixeddosingafliberceptregimen.
.Vascular endothelialgrowthfactor(VEGF)isakeyregulatorof angiogenesisinneovascularage-relatedmacular degeneration(nvAMD)andmonthlyintravitrealinjectionsof theanti-VEGFtherapiesranibizumabandbevacizumabhave shownimprovedvisualoutcomeswithsimilarefficacy [2] [3] . Studiesonaflibercept(arecombinantfusionproteinwhich bindsallVEGF-Aisoformsandplacentalgrowthfactors1 and2)suggestahigherbindingaffinitytoVEGFwith non-inferiorclinicaloutcomeswhenadministeredin2 monthlydosestotreatment-na觙venvAMDpatients [4] .New evidencesuggeststhatthemostfavourablelong-termvisual outcomesareseenwhenproactivecontinuousanti-VEGF treatmentsaregivenascomparedtosporadicoras-needed therapy [5] . Improvedvisualandanatomicaloutcomeshavealsobeen reportedinpatientswithpoorlyresponsivechoroidal neovascularisation(CNV)afterswitchingtoaflibercept treatment [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .Howeverunlikethefixeddosingregimenused intheseminalVIEWstudies [4] ,theseafliberceptstudiesand caseseriesmostlyhadshortfollow-upandfollowed (PRN),variabledosingortreatandextendregimens [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Datafromreallifebimonthlyfixeddosingstudiesof afliberceptarelackingincurrentliterature.Furthermore, resultsfrommajorclinicaltrialshaveoverallshownbetter visual improvementusingfixed proactivedosing regimens [4, [18] [19] comparedwithvariabledosinganti-VEGF regimens [20] [21] [22] [23] [24] . 
RESULTS

Patient Demographics and Baseline Characteristics
Eighty-eightpatients(107eyes)wereeligibletobeincluded intheswitchedafliberceptgroup,whilethetreatment-na觙ve afliberceptgrouphad51participants(58eyes [14] [15] [16] .Baselinevisualacuityand patientdemographicsinourstudyweresimilartothosefrom previousreports.Ourcohorthadfewerinjectionswith ranibizumabpriortocommencingfixeddosingaflibercept treatment,whichmaypartlyaccountforthesuperiorvisual outcomesweobserved.Differencesindosingregimencould alsobeacontributoryfactor.Ofnote,theonlystudiesto reportcomparableBCVAimprovementstoourstudyalso employedafixeddosingafliberceptregimen [7, 17] .Themean visualimprovementsreportedbyChang [7] andSingh [17] were+6.9lettersand+5.9lettersrespectivelyat 6mo,comparedwith+5.1lettersat6moinourswitched cohort.Moonda [25] reportedvisualimprovementsin29 treatmentrefractorynvAMD( =18)andPCV( =14)patients whereVAandOCTimprovedfrom0.58to0.55(=0.005) andfrom404to321 滋m(<0.001)respectivelyafter switchingtoaflibercept.Kawashima [26] inasmallgroup ofranibizumabresistantnvAMD( =15)andPCVpatients ( =26)reported1lineBCVAimprovementinPCVbutnot inAMDpatients.InasmallerstudybyOishi [27] (nvAMD=46andPCV=42),logMARBCVAimprovedfrom 0.36to0.21.Overall,themeanBCVAimprovementof+4.67 lettersinourna觙venvAMDpatientgroupiscomparabletoa recentlypublishedUKstudybyTalks [28] whichshowed a+5.1lettermeanimprovement. Chang et al [7] ,49 Fixed dosing-3 monthly, then bimonthly Retrospective 6 77.8 (±7.5 SD) 43 60.5 (20/62)
Bakall et al [6] ,36 Treat and extend after 3 loading doses Retrospective 6 79 (range 60-88) 42 62.5 (20/56) 1 Where previous studies have reported BCVA in logMAR, this was converted to ETDRS letter equivalents using a published method [24] . BCVA: Best-corrected visual acuity; CRT: Central retinal thickness; ETDRS: Early Treatment Diabetic Retinopathy Study; IQR: Interquartile range; SD: Standard deviation. Ferrone et al [9] ,221 -2 -300;0 14 -3
Cho et al [8] ,28 -2.5 -295;-21 20.2 -4.4
Chang et al [7] ,49 +6.9 55%≥5 letters 448.4; -89.1 34.9 40.8 5
Bakall et al [6] ,36 -2. [29] ,wherelogMARBCVAimprovedby 0.2linesafter3afliberceptinjectionsinswitchedpatientsbut marginallydecreasedby0.45lineswithoutfixeddosingat 12mo. Inanothervariabledosingstudy,Messenger [15] investigatedoutcomesfor109treatment-resistantnvAMD patientstreatedwithaflibercept,wheredosingwasbasedon cliniciandiscretion.Whilethemeannumberofinjections reportedbythisgroupissimilartothatofourstudy,patients lostonaverage-2lettersatlastfollow-up.Inaddition,the meannumberofclinicvisitsover1ywas8.7comparedwith 4forourfixeddosingregimen. Thepivotal VIEW studiesdemonstratednon-inferior outcomeswithareduceddosingafliberceptregimen comparedwithranibizumab,94%-96%oftreatment-na觙ve patientsmaintainingBCVAwithmeangainsof+8.3to9.3 lettersacrosstreatmentgroupsatoneyear [4] . [19] andANCHOR [18] trialsonranibizumabtreatmentfornvAMD.TheMARINA studytreatedpatientswithoccultandMCCNVlesions, findingvisualgainsofupto+7.2lettersat12mo [19] .By comparisontheANCHORstudyinvestigatedpatientswith predominantlyclassicCNVlesions,showingevengreater BCVAimprovementsofupto+11.3lettersat12mo [18] . AnalysingvisualoutcomesbyCNVsubtypeinourcohort alsorevealedgreatermeanvisualimprovementoverallfor eyeswithPCCNVcomparedtooccultandMCCNV.Larger studiesareneededtoevaluateCNVsubtypeasaprognostic factorinthetreatmentofnvAMDbyanti-VEGFagents. Strengthsofourstudyincludeitslargesamplesizeandthe useofproactivebimonthlyfixeddosingtreatments.Recent literatureshowslackofsimilarbimonthlyafliberceptstudies andthosereportedhaveverysmallsamplesizes [30] .Themain limitationofourstudyisitsretrospectivedesign.Further long-termfollow-upisneededtodeterminewhether improvementsinBCVAandOCTaremaintained.Apossible drawbackofthisdosingregimenisthepotentialfor over-treatingsomepatients,althougharecentstudybyPeden [5] publishedinOphthalmologyreportedfavourable long-termvisualoutcomeswithcontinuous anti-VEGF treatmentcomparedwithsporadic,as-neededtherapy. Contrastingly,bimonthlyfixeddosingregimensmayhavethe riskofundertreatingsomepatientsforwhommonthly afliberceptmaybemorebeneficial.However,thisappearsto beuntrueasseeninacaseseriesbyGrewal [14] where patientswerestartedon3monthlyloadingdosesof afliberceptbeforeeitherbeingswitchedtobimonthlydosing orcontinuedonmonthlytreatmentiftherewaspersistent fluidonOCT.Thiscaseseriesdidnotreportimprovedvisual outcomeswhencomparedtoourcohort. Insummary,weinvestigatedthevisualandanatomical outcomesofafixedbimonthlydosingafliberceptregimein poorlyresponsiveandtreatment-na觙venvAMDpatients. Significantimprovementsinvisualacuityat12monotedin theswitchedgroupcomparedbetterthanreportsfrom previouslypublishedstudies.Thenumberofaflibercept injectionswassimilartoreportswithotheranti-VEGFdosing regimens,whilevisualoutcomeswerebetterdespite considerablyfewermonitoringclinicvisitsusedinthisstudy. However,visualimprovementsfortreatment-na觙vepatients inourcohortdidnotreachVIEWtrialstandards,whichmay bepartlyduetodifferentproportionsofCNVsubtypes. Overall,fixeddosingappearstogivethebestlong-term visualoutcomescomparedwithothertypesofdosing regimens.Thisstatementissupportedfrombothourstudy andfromPeden [5] .Futurereal-lifeprospectivestudies withlongerfollow-upusingfixeddosingregimensreplicating clinicaltrialsareessential.Aformalcost-benefitanalysisof differenttreatmentregimenscouldalsohelpdeterminethe mosteffectivepathwayformanagingnvAMD.
